Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2A | Q12879 | 3/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.53 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | POLB | P06746 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 7/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16636630 | 0.88 | GRIN2A (0.67) | GRIN2AGRIN1GRIA2MAPTPOLB | |
| SCHEMBL16636491 | 0.80 | GRIN2A (0.82) | GRIN2AGRIN1GRIA2MAPTPOLB | |
| SCHEMBL16636489 | 0.80 | GRIN2A (0.82) | GRIN2AGRIN1GRIA2MAPTPOLB | |
| SCHEMBL16592136 | 0.77 | MAOA (0.52) | MAPTPOLBSMN1; SMN2TP53GAA | |
| SCHEMBL16637168 | 0.74 | GRIN2A (0.66) | GRIN2AGRIN1GRIA2MAPTPOLB | |
| SCHEMBL16637032 | 0.73 | GRIN2A (0.76) | GRIN2AGRIN1GRIA2MAPTPOLB | |
| SCHEMBL16636830 | 0.73 | GRIN2A (0.68) | GRIN2AGRIN1GRIA2MAPTPOLB | |
| SCHEMBL16637050 | 0.73 | GRIN2A (0.64) | GRIN2AGRIN1GRIA2MAPTPOLB | |
| SCHEMBL16636623 | 0.73 | GRIN2A (0.76) | GRIN2AGRIN1GRIA2MAPTPOLB | |
| SCHEMBL17958219 | 0.73 | GRIN2A (0.82) | GRIN2AGRIN1GRIA2MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647731-B2 | Thiazolopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-3415519-A1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2018-12-19 | — | — | EP | disclosed |
| US-20180244694-A1 | THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-08-30 | — | — | US | disclosed |
| EP-3055315-B1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2018-07-25 | — | — | EP | disclosed |
| US-9988400-B2 | Thiazolopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| EP-3055315-A1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2016-08-17 | — | — | EP | disclosed |
| US-20160222033-A1 | THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| WO-2015052226-A1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647731-B2 | Thiazolopyrimidinones and methods of use thereof | TPMT, THPO, CYP11B2 | GRIN2A 2506/4885GRIN1 2250/4885GRIA2 2761/4885 |
| US-20180244694-A1 | THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF | TPMT, THPO, CYP11B2 | GRIN2A 2506/4885GRIN1 2250/4885GRIA2 2761/4885 |
| US-20160222033-A1 | THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF | TPMT, THPO, CYP11B2 | GRIN2A 2506/4885GRIN1 2250/4885GRIA2 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.